resurg
sever
acut
respiratori
syndrom
sar
still
threat
caus
agent
remain
anim
reservoir
fulli
understood
sporad
case
continu
report
develop
high
titer
antisar
hyperimmun
globulin
provid
altern
pathway
emerg
futur
prevent
treatment
sar
method
sar
coronaviru
cov
isol
identifi
differ
cantones
onset
sar
patient
immunogen
prepar
sarscov
strain
six
health
hors
immun
time
serum
collect
period
measur
profil
specif
igg
neutral
antibodi
use
indirect
enzymelink
immunosorb
assay
microneutr
test
sera
collect
larg
amount
peak
igg
precipit
use
ammonium
sulphat
subsequ
digest
pepsin
product
purifi
use
anionexchang
chromatographi
obtain
f
ab
fragment
result
specif
igg
neutral
antibodi
titer
peak
approxim
week
first
immun
maximum
valu
sera
collect
peak
purifi
fragment
approxim
g
f
ab
obtain
litr
antiserum
puriti
titer
could
neutral
strain
sarscov
well
conclus
research
provid
viabl
strategi
prevent
treatment
sar
coronaviru
infect
equin
hyperimmun
globulin
purpos
combat
resurg
sar
sever
acut
respiratori
syndrom
sar
emerg
southeast
asia
late
subsequ
spread
intern
caus
agent
quickli
identifi
previous
unknown
member
coronavirida
famili
accord
world
health
organ
apr
sar
coronaviru
infect
peopl
variou
countri
worldwid
caus
approxim
death
although
sar
infect
human
be
contain
infectioncontrol
measur
resurg
still
threat
caus
agent
remain
anim
reservoir
fulli
understood
sporad
case
continu
report
singapor
taiwan
mainland
china
specif
vaccin
effect
drug
current
avail
sarscov
effect
vaccin
develop
best
hope
treatment
infect
prevent
control
futur
outbreak
develop
passiv
immunotherapi
sarscovspecif
antibodi
immunoglobulin
effect
method
use
protect
anim
coronaviru
transmiss
gastroenter
viru
tgev
mous
hepat
viru
bovin
coronaviru
clinic
evid
serum
recov
patient
effect
infect
individu
observ
suggest
hyperimmun
serum
could
develop
passiv
treatment
sar
use
equin
antisera
emerg
prevent
treatment
infecti
diseas
proven
effect
safe
strategi
rabi
viru
therefor
immunoprophylaxi
treatment
sar
coronaviru
infect
equin
hyperimmun
globulin
might
viabl
strategi
control
sar
viru
strain
sever
acut
respiratori
syndrom
coronaviru
isol
sampl
differ
cantones
onset
sar
patient
sequenc
compar
show
certain
differ
tabl
viral
titr
sarscov
strain
determin
tissuecultureinfect
dose
tcid
ml
tcid
ml
reedmuench
method
respect
antigen
prepar
strain
use
antigen
immun
african
green
monkey
kidney
cell
infect
sar
cov
strain
cultiv
serumfre
minimum
essenti
medium
mem
gibco
observ
period
cytopath
effect
cpe
cytopathi
reach
infect
cell
frozen
thaw
time
subsequ
centrifug
min
cell
debri
decant
supernat
collect
store
use
viral
supernat
centrifug
h
precipit
dilut
phosphat
buffer
salin
pb
use
antigen
immun
anim
immun
six
yearold
healthi
hors
provid
quartermast
univers
pla
immun
hors
perform
accord
state
enzymelink
immunosorb
assay
elisa
sever
acut
respiratori
syndrom
coronaviru
specif
igg
measur
use
indirect
enzymelink
immunosorb
assay
elisa
whole
purifi
sarscov
antigen
brief
polystyren
micro
well
plate
coat
antigen
contain
viru
protein
carbonatebicarbon
buffer
ph
well
wash
time
pb
block
bovin
serum
locu
locu
pb
contain
pbst
h
wash
pbst
serial
twofold
dilut
serum
sampl
final
ad
plate
incub
h
horseradish
peroxidas
hrp
conjug
goat
antihors
igg
sigma
usa
dilut
pb
ad
follow
wash
follow
incub
h
plate
wash
substrat
tetramethylbenzidin
tmb
solut
sigma
ad
well
incub
min
reaction
stop
ad
mmoll
sulfur
acid
absorb
valu
nm
measur
micropl
reader
model
biorad
igg
antibodi
titer
defin
highest
dilut
serum
ratio
neg
serum
greater
microneutr
assay
neutral
assay
perform
accord
modifi
oper
procedur
manual
virolog
investig
polio
formul
http
wwwwhoch
programmesgpvgenglishavailgpvcatalogcatloghtm
serum
sampl
serial
dilut
twofold
dilut
mem
mainten
medium
final
dilut
incub
equal
volum
tcid
purifi
strain
h
virusantibodi
mix
inocul
onto
cell
cellsml
monolay
plate
approxim
well
normal
cell
control
viru
control
ad
mainten
medium
unneutr
activ
viru
dilut
respect
plate
incub
cpe
develop
viru
control
cell
control
remain
normal
neutral
antibodi
titer
highest
dilut
serum
protect
cultur
challeng
viru
viru
control
serum
show
complet
cpe
purif
immunoglobulin
hors
antiserum
thaw
water
bath
ad
satur
ammonium
sulphat
solut
mix
gentli
min
centrifug
precipit
gener
collect
store
overnight
ammonium
sulphat
precipit
dilut
use
equal
volum
nacl
solut
dialyz
remov
salt
ph
adjust
moll
hcl
hors
serum
ad
pepsin
sigma
solut
digest
h
h
h
h
h
h
respect
reaction
stop
adjust
ph
use
moll
naoh
digest
materi
ultrafiltr
anionexchang
separ
ultrafiltr
materi
perform
use
diethylaminoethyl
deae
sepharos
fast
flow
pharmacia
column
preequilibr
ml
buffer
mmol
trishcl
ph
ultrafiltr
materi
pump
column
nm
elut
materi
monitor
follow
pump
fresh
buffer
nm
return
baselin
unbound
materi
correspond
f
ab
fragment
collect
store
bound
contamin
elut
regener
column
use
gradient
buffer
b
contain
mmol
trishcl
ph
mmoll
nacl
ph
product
obtain
use
anionexchang
chromatographi
ultrafiltr
concentr
ad
moll
aminoacet
acid
obtain
stock
solut
accord
demand
standard
biolog
product
product
characterist
eg
ph
protein
concentr
bacteri
endotoxin
content
detect
use
serial
procedur
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
nonreduc
sdspage
gel
use
buffer
system
describ
laemmli
use
monitor
digest
process
check
trace
undigest
igg
unwant
materi
viru
sarscov
electron
microscop
visual
characterist
coronaviru
particl
form
observ
figur
six
health
hors
immun
purifi
sarscov
strain
titer
total
antisarscov
igg
measur
use
indirect
elisa
dynam
chang
specif
antisarscov
igg
antibodi
titer
shown
figur
sera
distinctli
show
posit
reaction
rang
specif
igg
antibodi
titer
titer
specif
igg
antibodi
increas
rapidli
week
peak
week
first
immun
maximum
valu
titer
neutral
antibodi
antiserum
measur
use
microneutr
test
kinet
format
neutral
antibodi
follow
immun
hors
observ
figur
neutral
antibodi
partial
detect
third
immun
neutral
antibodi
titer
immun
hors
increas
rapidli
first
immun
neutral
antibodi
titer
equin
reach
highest
level
continu
increas
reach
highest
titer
cross
neutral
respons
strain
use
microneutr
test
vitro
measur
hyperimmun
sera
sarscov
strain
result
indic
hors
antiserum
induc
inactiv
sarscov
strain
capabl
neutral
sarscov
strain
complet
f
ab
prepar
digest
pepsin
differ
time
point
assess
use
sdspage
figur
result
indic
igg
could
digest
complet
ph
within
h
unwant
protein
band
eg
albumin
transferrin
could
elimin
well
reaction
stop
adjust
ph
use
moll
naoh
anionexchang
chromatographi
salt
gradient
perform
remov
high
molecular
weight
aggreg
pepsin
digest
antisera
buffer
separ
peak
figur
materi
peak
concentr
final
g
f
ab
fragment
obtain
litr
antiserum
puriti
titer
serum
specif
igg
antibodi
shown
highest
dilut
serum
ratio
greater
titer
neutral
antibodi
purif
detect
product
obtain
dissolv
suitabl
volum
nacl
adjust
protein
concentr
gl
ph
determin
bacteri
endotoxin
content
also
detect
eu
ml
termin
product
accord
standard
sfda
store
sever
acut
respiratori
syndrom
result
import
challeng
medic
commun
avail
specif
vaccin
effect
drug
use
sarscov
control
depend
prompt
detect
isol
case
good
infect
control
hospit
trace
quarantin
contact
widespread
clinic
success
applic
immunoglobulin
deriv
heterogen
anim
rabi
long
histori
passiv
administr
neutral
antibodi
could
effect
strategi
emerg
prophylaxi
treatment
sar
result
research
indic
healthi
hors
immun
sarscov
strain
induc
gener
effect
specif
neutral
antibodi
analysi
indic
sequenc
differ
exist
among
sarscov
sequenc
sarscov
strain
differ
sarscov
strain
tabl
immunoglobulin
prepar
sarscov
strain
isol
april
could
neutral
anoth
sarscov
strain
isol
sar
patient
februari
show
sarscov
strain
own
ident
similar
neutral
epitop
heterogen
antisera
use
treatment
possibl
result
anaphylactoid
sever
acut
sideeffect
avoid
sideeffect
caus
hors
antiserum
igg
sarscov
digest
pepsin
purifi
anionexchang
separ
exclud
immunogen
fc
fragment
retain
special
activ
bind
antigen
f
ab
fraction
titer
neutral
f
ab
sarscov
detect
higher
level
approxim
g
f
ab
fragment
obtain
litr
antiserum
puriti
efficaci
vaccin
implement
effect
epidemiolog
infect
control
measur
given
presenc
effect
antisarscov
agent
sar
like
remain
major
health
threat
world
articl
provid
altern
pathway
prevent
treatment
sar
purpos
combat
resurg
sar
profil
antibodi
titer
observ
effect
specif
neutral
hyperimmunoglobulin
prepar
result
indic
kinet
induc
specif
igg
neutral
antibodi
similar
figur
data
pave
way
develop
inactiv
sar
vaccin
